Skip to Content

Join the 'Schizophrenia' group to help and get support from people like you.

Schizophrenia News

Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia

Allergan Receives FDA Approval for Vraylar (cariprazine) in the Maintenance Treatment of Schizophrenia

Posted 7 days ago by Drugs.com

DUBLIN, Nov. 13, 2017 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. Vraylar is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder.1 "Schizophrenia is one of the most challenging mental health disorders to manage – particularly due to the complexity of patient symptoms, varying response to treatment and high rates of relapse," said Dr. Herbert Meltzer, Professor of Psychiatry and Behavioral Sciences at Northwestern Feinberg School of Medicine. "The goal of clinicians is to minimize relapses, which can cause significant personal distress, and can often have serious implications for a patient's h ... Read more

Related support groups: Schizophrenia, Vraylar, Cariprazine

FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication

Posted 8 days ago by Drugs.com

November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal. “Being able to track ingestion of medications prescribed for mental illness may be ... Read more

Related support groups: Depression, Bipolar Disorder, Abilify, Schizophrenia, Aripiprazole, Abilify Maintena, Abilify Discmelt, Abilify MyCite

FDA OKs First 'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken

Posted 8 days ago by Drugs.com

TUESDAY, Nov. 14, 2017 – Offering both the promise of better patient compliance with health care, but also fears of a medical "Big Brother," a newly approved "digital pill" allows physicians to track whether or not it's been ingested by patients. The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. As explained in an FDA news release, the pill contains a sensor that communicates with a wearable patch. This patch in turn sends signals to the patients' smartphone, telling them whether or not they've taken the pill, along with the pertinent dates and times. "Patients can also permit their caregivers and physician to access the information through a web-based portal," the FDA noted – opening the ... Read more

Related support groups: Bipolar Disorder, Abilify, Schizophrenia, Mania, Schizoaffective Disorder, Aripiprazole, Abilify Maintena, Abilify Discmelt, Aristada, Abilify MyCite

'Digital Pill' Tells Doctor When Patient Takes It

Posted 8 days ago by Drugs.com

TUESDAY, Nov. 14, 2017 – The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a message to a wearable patch that the medication's been taken. This allows the patient and doctor to track the medication's use via smartphone. Abilify, first approved in 2012, is now OK'd to treat schizophrenia, manic depression and bipolar disorder, the FDA said in a news release. "Being able to track ingestion of medications prescribed for mental illness may be useful for some patients," said Dr. Mitchell Mathis, director of the agency's Division of Psychiatry Products. Abilify MyCite hasn't been proven to improve patient compliance with taking medication on a prescribed schedule, the FDA stressed. And the drug shouldn't be used in an attempt to ... Read more

Related support groups: Depression, Bipolar Disorder, Abilify, Schizophrenia, Schizoaffective Disorder, Aripiprazole, Abilify Maintena, Abilify Discmelt, Aristada, Abilify MyCite

Genes May Explain Why Some Don't Respond to Bipolar Drug

Posted 14 days ago by Drugs.com

WEDNESDAY, Nov. 8, 2017 – In a finding that pulls the roots of two mental illnesses closer together, researchers say people with bipolar disorder that's resistant to the drug lithium have a high number of genes associated with schizophrenia. Since the 1950s, lithium has been widely used to treat bipolar disorder. The drug stabilizes mood swings – the highs and lows associated with the disorder – and reduces the risk of suicide. But nearly one-fourth of patients don't respond to the drug and about 30 percent have only a partial response. To learn more about why some don't respond to the treatment, researchers studied the genetics of more than 2,500 bipolar patients who were given lithium. "We found that patients clinically diagnosed with bipolar disorder who showed a poor response to lithium treatment all shared something in common: a high number of genes previously identified for ... Read more

Related support groups: Bipolar Disorder, Seroquel, Abilify, Lithium, Schizophrenia, Mania, Latuda, Risperidone, Zyprexa, Schizoaffective Disorder, Quetiapine, Risperdal, Geodon, Saphris, Seroquel XR, Olanzapine, Rexulti, Invega, Clozapine, Aripiprazole

Schizophrenia Affects Brain's Communication Network

Posted 18 Oct 2017 by Drugs.com

WEDNESDAY, Oct. 18, 2017 – The mental illness schizophrenia disrupts the brain's entire communication network, a new study suggests. This research disputes a theory that schizophrenia is caused by wiring problems only in certain parts of the brain. The findings could help direct future research into the disorder that affects more than 21 million people worldwide, the researchers said. "We can definitively say for the first time that schizophrenia is a disorder where white matter wiring is frayed throughout the brain," said study co-lead author Sinead Kelly, formerly a researcher at the Neuroimaging and Informatics Institute at the University of Southern California's Keck School of Medicine. The study included a review of brain scans from more than 1,900 people worldwide with schizophrenia. The researchers analyzed the "white matter" – the fatty brain tissue that enables brain cells ... Read more

Related support groups: Depression, Schizophrenia, Schizoaffective Disorder, Diagnosis and Investigation, Head Imaging

Americans More Open About Mental Health Issues, But Stigma Lingers

Posted 3 Oct 2017 by Drugs.com

TUESDAY, Oct. 3, 2017 – Americans may be more willing to talk about mental health issues these days, but misperceptions and stigmas persist, a new survey finds. The survey, of more than 3,000 U.S. adults, found that 70 percent said they feel people are more open to discussing mental health compared with a decade ago. Most respondents also said they'd want to help a family member or friend struggling with depression or other mental health conditions. On the other hand, age-old misperceptions were still common. Many people, for example, thought that mental health disorders were at least partially driven by "personal failings." "That's certainly disappointing," said Dr. Don Mordecai, director of mental health and addiction medicine services at Kaiser Permanente, in Oakland, Calif., which commissioned the poll. "These are true brain conditions," Mordecai said, "and we have to get away from ... Read more

Related support groups: Depression, Anxiety, Bipolar Disorder, Anxiety and Stress, Major Depressive Disorder, Obsessive Compulsive Disorder, Post Traumatic Stress Disorder, Schizophrenia, Paranoid Disorder, Schizoaffective Disorder, Dysthymia, Psychiatric Disorders, Severe Mood Dysregulation

Your Sociability May Hinge on 'Love Hormone'

Posted 29 Sep 2017 by Drugs.com

FRIDAY, Sept. 29, 2017 – If you like to hang out with friends, it might be due to the "love hormone" oxytocin, a new mouse study suggests. Oxytocin promotes socialization by triggering pleasurable feelings when people get together, said Stanford University researchers. "Our study reveals new insights about the brain circuitry behind social reward, the positive experience you often get when you run into an old friend or meet somebody you like," said study senior author Dr. Robert Malenka. He's associate chair of psychiatry and behavioral science at Stanford's School of Medicine. "The reward circuitry is crucial to our survival because it rewards us for doing things that have, during our evolutionary history, tended to enhance our survival, our reproduction and the survival of our resulting offspring," he explained in a university news release. For example, when you're hungry, food ... Read more

Related support groups: Anxiety, Anxiety and Stress, Social Anxiety Disorder, Schizophrenia, Schizoaffective Disorder, Autism, Asperger Syndrome

Parents Say Schools Don't Help Kids With Mental Health, Chronic Disease

Posted 18 Sep 2017 by Drugs.com

MONDAY, Sept. 18, 2017 – Many parents don't believe schools are prepared to help students with mental health problems and serious physical health issues, a new survey finds. While 77 percent of parents were certain that schools would be able to provide first aid for minor issues such as cuts, they were less confident that schools could respond to more challenging health situations. For example, only 38 percent believed schools could assist a student suspected of having a mental health problem. The national poll on children's health was released Monday by the C.S. Mott Children's Hospital at the University of Michigan. "Parents feel schools can handle basic first aid, but are less sure about urgent health situations such as an asthma attack, epileptic seizure, or serious allergic reaction," Sarah Clark, poll co-director, said in a university news release. "And they have the most ... Read more

Related support groups: Depression, Anxiety, Bipolar Disorder, Anxiety and Stress, Major Depressive Disorder, Attention-Deficit Hyperactivity Disorder (ADHD), Schizophrenia, Borderline Personality Disorder, Oppositional Defiant Disorder, Dysthymia, Psychiatric Disorders, Anorexia, Aggressive Behavior

Magnetic Brain Stimulation May Quiet 'Voices' in Schizophrenia

Posted 7 Sep 2017 by Drugs.com

THURSDAY, Sept. 7, 2017 – A therapy that stimulates a region of the brain linked to language may help quiet the hallucinatory "voices" that often plague schizophrenia patients, new research suggests. A voice hallucination "seems very real for the patient, and very disturbing," explained study author Dr. Sonia Dollfus. "The voices can be felt inside or outside the brain." Dollfus is head of the mental health department with the Hospital Center University of Caen in France. Typically, the 70 percent of schizophrenia patients who experience these voices are treated with antipsychotics, she said. Unfortunately, not all patients respond, but this new treatment may be a "very promising" alternative, she added. Dollfus noted that voice hallucinations can involve just one voice or several voices, speaking intermittently or constantly. In some cases the voices – which can be adversarial or ... Read more

Related support groups: Seroquel, Abilify, Lithium, Schizophrenia, Latuda, Risperidone, Zyprexa, Schizoaffective Disorder, Quetiapine, Risperdal, Geodon, Saphris, Seroquel XR, Olanzapine, Haldol, Rexulti, Invega, Clozapine, Haloperidol, Aripiprazole

Health Tip: Mental Disorders Are Common

Posted 9 Aug 2017 by Drugs.com

-- More than 43 million American adults, 18 percent of the U.S. population, had a mental disorder in the past year, the most recent surveys cited by the Substance Abuse and Mental Health Services Administration (SAMHSA) show. These disorders – characterized by significant changes in mood, thoughts or behavior – often make carrying out daily activities more difficult and impair relationships with family and friends. If you or a loved one has a mental disorder, the agency suggests: Don't blame yourself or the person with the disorder. It's not an "attitude problem," but a medical condition. Listen to the person carefully, but don't judge him or her. Ask gently if you can make an appointment to see a health professional. The affected person may not be able to do this. As worried as you may be about the affected person, avoid the temptation to argue or convince the person of a problem. ... Read more

Related support groups: Depression, Anxiety, Bipolar Disorder, Panic Disorder, Anxiety and Stress, Major Depressive Disorder, Post Traumatic Stress Disorder, Social Anxiety Disorder, Schizophrenia, Mania, Borderline Personality Disorder, Eating Disorder, Psychosis, Dysthymia, Psychiatric Disorders

Poor Sleep May Worsen Suicidal Thoughts

Posted 28 Jun 2017 by Drugs.com

WEDNESDAY, June 28, 2017 – Sleep problems may provide early clues about worsening suicidal thoughts in at-risk young adults as well as a potential way to intervene, a new study suggests. "Suicide is the tragic outcome of psychiatric illness interacting with multiple biological, psychological and social risk factors," said lead author Rebecca Bernert. She is a suicidologist and assistant professor of psychiatry and behavioral sciences from Stanford University Medical School. "Sleep disturbances stand apart from other risk factors because they are visible as a warning sign, yet non-stigmatizing and highly treatable. This is why we believe they may represent an important treatment target in suicide prevention," she said in a university news release. How could sleep potentially prevent a suicide? "Sleep is a barometer of our well-being, and directly impacts how we feel the next day. We ... Read more

Related support groups: Depression, Anxiety, Bipolar Disorder, Anxiety and Stress, Sleep Disorders, Insomnia, Major Depressive Disorder, Obsessive Compulsive Disorder, Fatigue, Post Traumatic Stress Disorder, Social Anxiety Disorder, Schizophrenia, Mania, Borderline Personality Disorder, Dysthymia, Psychiatric Disorders, Drowsiness, Hypersomnia, Severe Mood Dysregulation, Cyclothymic Disorder

FDA Medwatch Alert: Paliperidone Extended-Release Tablets 3mg by Teva Pharmaceuticals: Recall - Dissolution Test Failure

Posted 19 Jun 2017 by Drugs.com

ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A, expiration 6/2018, NDC 0591-3693-19, that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the consumer/user level.  This recall is being carried out due to failing test results for dissolution. Teva cannot at this time exclude the potential for additional tablets to be below specification. Taking a product for the treatment of schizophrenia and schizoaffective disorders that has failed dissolution could result in less drug being absorbed. If two or more consecutive dosing regimens are with affected product, a failure to maintain therapeutic levels could occur, which could reduce effectiveness in treating a patient’s mental and/or moo ... Read more

Related support groups: Schizophrenia, Schizoaffective Disorder, Invega, Invega Sustenna, Paliperidone, Invega Trinza

FDA Approves Two-Month Aristada for Treatment of Schizophrenia

Posted 7 Jun 2017 by Drugs.com

DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada is now FDA-approved in four doses and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every six weeks and 1064 mg once every two months) and can be initiated at any dose or interval, offering an unprecedented range of flexibility to patients and healthcare providers. The new two-month dose is expected to be available in mid-June. “We designed Aristada to offer flexibility to meet the real-world needs of patients suffering from schizophrenia and the healthcare professionals providing their care. As the first and only long-acting atypical antipsychotic approved in three dosing durations ... Read more

Related support groups: Schizophrenia, Aripiprazole, Aristada

Chronic Pain Common in Adults With Depression, Anxiety

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Chronic pain afflicts about half of adults who have anxiety or depression, a new study finds. More than 5,000 adults in Brazil diagnosed with anxiety or mood disorders such as depression and bipolar disorder were asked about other health problems. Among those with a mood disorder, half reported chronic pain; 33 percent, respiratory diseases; 10 percent, heart disease; 9 percent, arthritis; and 7 percent, diabetes. Among those with anxiety, 45 percent reported chronic pain; 30 percent, respiratory diseases; and 11 percent each for arthritis and heart disease. Adults with two or more chronic diseases had an increased risk of a mood or anxiety disorder. High blood pressure was associated with both disorders at 23 percent, according to the Columbia University study published online June 1 in the Journal of Affective Disorders. Senior author Dr. Silvia Martins said ... Read more

Related support groups: Pain, Depression, Anxiety, Generalized Anxiety Disorder, Bipolar Disorder, Suboxone, Anxiety and Stress, Oxycodone, Lexapro, Zoloft, Tramadol, Cymbalta, Hydrocodone, Methadone, Percocet, Effexor, OxyContin, Prozac, Vicodin, Major Depressive Disorder

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Schizoaffective Disorder, Psychiatric Disorders

Related Drug Support Groups

Seroquel, Abilify, Latuda, risperidone, Zyprexa, Risperdal, quetiapine, Geodon, Saphris, view more... Seroquel XR, olanzapine, Rexulti, Invega, clozapine, aripiprazole, Clozaril, Vraylar, Thorazine, Zyprexa Zydis, ziprasidone, Fanapt, Invega Sustenna, chlorpromazine, paliperidone, asenapine, Risperdal Consta, Stelazine, Navane, Mellaril, loxapine, brexpiprazole, iloperidone, thioridazine, Zyprexa Intramuscular, thiothixene, Risperdal M-Tab, trifluoperazine, Abilify Maintena, Sparine, lurasidone, Abilify Discmelt, promazine, Zyprexa Relprevv, Invega Trinza, molindone, Adasuve, Versacloz, mesoridazine, Aristada, reserpine, Mellaril-S, Loxitane IM, Loxitane C, Serentil, Moban, Zaponex, Denzapine, Clozapine Synthon, Clopine, Ormazine, FazaClo, cariprazine, Loxitane, Abilify MyCite